← Every company
Shionogi & Co Ltd Patents
What Shionogi & Co Ltd has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
SGIOY on carbonthat →Filings on file
48
Granted
2
Still pending
46
Filed under
5 names
48 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| EDARAVONE SUSPENSION FOR ORAL ADMINISTRATIONA61P 21/00, A61K 9/10, A61K 31/4152, A61P 25/28, A61P 21/02, A61P 25/00, A61K 9/0053, A61K 9/0095, A61K 9/16, A61K 47/26, A61K 47/32, A61K 47/36, A61K 47/38Filed as Shionogi Inc.2026-04-13Tetsuo HAYAMA | pending |
| PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENTA61P 31/18, A61K 31/5383, A61K 31/4439, A61K 31/513, A61K 31/53, A61K 31/5386, A61K 31/56, A61K 31/63, A61K 31/635, A61K 45/00, A61K 45/06, A61K2300/00Filed as Shionogi & Co., Ltd.2026-01-23Tomokazu YOSHINAGA | pending |
| URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAMEA61P 31/14, C07D 401/14, C07D 491/107, A61P 43/00, A61K 31/513, A61K 31/527, C07D 401/04, C07D 401/12, C07D 403/14, C07D 405/14, C07D 409/14, C07D 413/14, C07D 417/14, C07D 471/04, C07D 471/08, C07D 487/04, C07D 487/08, C07D 487/10, C07D 487/18, C07D 491/10, C07D 491/20, C07D 498/10, C07D 498/18, C07D 519/00, C12N 9/506, C12Q 1/37, G01N 33/56983Filed as Shionogi & Co., Ltd.2026-01-06Jun SATO | pending |
| APPARATUS AND METHOD FOR TAKING OUT COMPOSITE FROM FLOW PATHB01F 35/75, B01F 35/221, B01F 25/43, B01J 4/007, B01J 4/008Filed as Shionogi Pharma Co., Ltd.2025-12-24Takashi MATSUZAKI | pending |
| APPARATUS AND METHOD FOR MANUFACTURING COMPOSITEA61K 9/127, B01F 35/22162, B01F 35/2215, B01F 33/301, B01F 35/7547, B01F 35/71805, B01F 35/213, B01F 25/43, B01F 23/45, B01F2101/22Filed as Shionogi Pharma Co., Ltd.2025-12-24Takashi MATSUZAKI | pending |
| PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEA61K 31/4152, A61P 25/28, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 47/02, A61K 47/18, A61K 47/26, A61K 47/32, A61K 47/34, A61K 47/36Filed as Shionogi Inc.2025-12-17Hidetoshi SHIMIZU | pending |
| PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASEA61P 1/16, A61K 31/4184, C07D 235/26, A61P 43/00, A61P 3/06, A61P 3/10, A61P 35/00, A61K 31/53, A61K 31/575, A61K 38/26, A61K 45/06, A61K2300/00, C07D 405/12, C07J 9/005Filed as Shionogi & Co., Ltd.2025-12-09Hideo YUKIOKA | pending |
| METHOD FOR IMPROVING ATTENTION FUNCTION OF A SUBJECT, METHOD FOR IMPROVING FLUENCY OF A SUBJECT, AND METHOD FOR IMPROVING CONGNITIVE FUNCTION OF A SUBJECTA61H 23/0236, A61H2201/5005, A61H2201/5048, G10K 15/02Filed as Shionogi & Co., Ltd.2025-12-09Yoshiki NAGATANI | pending |
| DOSAGE OF BALOXAVIR MARBOXIL FOR PEDIATRIC PATIENTSA61K 31/5383, A61P 31/16, A61K 9/0095, A61K 9/1694, A61K 47/02, A61K 47/14, A61K 47/22, A61K 47/26, A61K 47/32, A61K 47/38Filed as Shionogi & Co., Ltd.2025-11-11Stefan De Buck | pending |
| PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEA61K 31/4152, A61P 25/28, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 47/02, A61K 47/18, A61K 47/26, A61K 47/32, A61K 47/34, A61K 47/36Filed as Shionogi Inc.2025-10-27Hidetoshi SHIMIZU | pending |
| PREDICTION SYSTEM, PREDICTION METHOD, AND PROGRAMG16H 50/30, G06Q 10/063114, G16H 50/70, G16H 50/20, G16H 40/63, G16H 10/20, G06Q 10/06, G06Q 10/1091Filed as SHIONOGI & CO., LTD.2025-10-02Hiroki IWAMOTO | pending |
| PYRIDAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOFFiled as SHIONOGI & CO., LTD.2025-07-31Toshihiko IWAYAMA | pending |
| METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOFA61P 3/10, C07D 403/12, A61P 43/00, A61K 31/4155Filed as Shionogi & Co., Ltd.2025-07-07Tomoya MIURA | pending |
| CAPSULE OR GRANULES CONTAINING PDE4 INHIBITORA61K 31/44, A61K 9/4808, A61K 9/4816, A61K 9/4833, A61K 9/4858, A61K 9/4866Filed as Shionogi & Co., Ltd.2025-06-20Naoya MIZUTANI | pending |
| Nitrogen-Containing Heterocycle with Serotonin Receptor-Binding Activity and Carbocyclic DerivativeC07D 487/04, A61K 31/415, A61K 31/4184, A61K 31/423, A61K 31/427, A61K 31/428, A61K 31/433, A61K 31/437, A61K 31/4375, A61K 31/4439, A61K 31/444, A61K 31/4725, A61K 31/497, A61K 31/4985, A61K 31/501, A61K 31/506, C07D 213/74, C07D 231/16, C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/04, C07D 403/12, C07D 405/14, C07D 413/12, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04, C07D 513/04Filed as Shionogi & Co., Ltd.2025-06-06Takuya Oguma | pending |
| METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEAFiled as SHIONOGI-APNIMED SLEEP SCIENCE, LLC2025-06-04LUIGI TARANTO-MONTEMURRO | pending |
| AROMATIC HETEROCYCLE DERIVATIVES AND AROMATIC CARBOCYCLE DERIVATIVES HAVING PDE4D INHIBITORY ACTIVITYFiled as SHIONOGI & CO., LTD.2025-05-16KAYOKO HATA | pending |
| USE OF PYRIDINE DERIVATIVE WHICH IS TRPV1 ANTAGONISTA61K 31/496, A61P 25/00Filed as Shionogi & Co., Ltd.2025-04-22Hidekuni YAMAKAWA | pending |
| POST-OPERATIVE DELIRIUM SUPPRESSANTA61K 31/57, A61K 31/573, A61K 31/575, A61P 25/28, A61P 43/00, A61P 25/02, A61P 25/18, A61P 25/00, A61K 9/0053, A61K 31/568, A61K 31/58, A61K 45/00Filed as Shionogi & Co., Ltd.2025-04-16Bun AOYAMA | pending |
| EDARAVONE SUSPENSION FOR ORAL ADMINISTRATIONA61K 31/4152, A61P 21/00, A61K 9/0053, A61K 9/16, A61K 47/32, A61K 47/36Filed as Shionogi Inc.2025-04-09Tetsuo HAYAMA | pending |
| FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECTA61K 31/519, C07D 405/14, A61K 31/4184, A61K 31/4355, A61K 31/4375, A61K 31/439, A61K 31/444, A61K 31/4725, A61K 31/4741, A61K 31/498, A61K 31/4985, C07D 405/06, C07D 471/04, C07D 471/18, C07D 491/056, C07D 519/00Filed as Shionogi & Co., Ltd.2025-03-17Misato KITAMURA FUJIWARA | pending |
| MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITYC07D 405/14, A61P 43/00, A61P 3/04, A61P 3/10, A61K 31/4439, C07D 401/14, C07D 413/14, C07D 471/04Filed as Shionogi & Co., Ltd.2025-03-17Yuji NISHIURA | pending |
| NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOFC07D 487/04, A61P 21/00, A61P 9/10, A61P 19/00, A61P 43/00, A61P 3/00, A61P 3/06, A61P 3/10, A61P 9/12, A61P 9/04, A61P 11/00, A61P 25/00, A61P 35/00, A61K 31/437, A61K 31/4725, A61K 31/4985, A61K 31/506, C07D 498/04, C07D 519/00, C12N 9/99Filed as SHIONOGI & CO., LTD.2025-02-13Takaki Maeba | pending |
| COMPOSITION AND METHOD FOR EVALUATING RESPONSIVENESS OF EDARAVONEA61K 31/4152, C12Q 1/6883, A61P 21/00, A61P 25/28, A61P 25/00, C12Q2600/106, C12Q2600/136, C12Q2600/158Filed as Shionogi Inc.2024-12-30Aki KUSUNOKI | pending |
| NOVEL Nav1.7 MONOCLONAL ANTIBODYC07K 16/18, C07K 16/28, A61P 25/02, A61P 25/04, A61P 29/02, A61P 29/00, A61P 17/04, A61K 39/395, A61K2039/505, C07K 16/00, C07K2317/24, C07K2317/34, C07K2317/565, C07K2317/76, C07K2317/92, C12N 15/63Filed as Shionogi & Co., Ltd.2024-12-23Mai YOSHIKAWA | pending |
| CONTENT DISTRIBUTION APPARATUS, CONTENT PLAYBACK APPARATUS, AND COGNITIVE FUNCTION IMPROVEMENT SYSTEMA61M 21/00, G10K 15/02, A61M 21/02, A61M2021/0027, A61M2205/3553, A61M2205/3584, A61M2205/3592, A61M2205/502, G06F 3/165, H04R 3/04Filed as Shionogi & Co., Ltd.2024-12-18Yoshiki NAGATANI | pending |
| CRYSTAL OF DIHYDROPYRIDINONE DERIVATIVE OR SOLVATE THEREOFC07D 491/20, A61P 43/00, A61P 3/04, A61K 31/438, A61K 31/444, C07B2200/13Filed as Shionogi & Co., Ltd.2024-12-11Katsuji SUGITA | pending |
| SYSTEM, METHOD, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUMA61B 5/125, G10K 15/02, G16H 10/00, A61B 5/16, A61B 5/4088, A61B 5/4803, A61B 5/4833, A61B 5/4836, A61B 5/7405, A61B 5/743, A61M 21/02Filed as Shionogi & Co., Ltd.2024-12-03Yoshiki NAGATANI | pending |
| ANTIBODY THAT BINDS TO CANNABINOID TYPE 1 RECEPTORSA61P 1/16, C07K 16/28, A61P 3/04, A61P 3/10, A61K2039/505, A61K2039/545, C07K2317/24, C07K2317/565, C07K2317/622, C07K2317/76, C07K2317/92Filed as SHIONOGI & CO., LTD.2024-12-02Mai YOSHIKAWA | pending |
| PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOFC07D 498/14, A61P 43/00, A61P 31/12, A61P 31/16, A61K 31/5383, C07B2200/13Filed as Shionogi & Co., Ltd.2024-09-20Makoto KAWAI | pending |
| INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOFA61K 31/416, A61K 31/506, C07D 231/56, C07D 403/04, A61P 21/00, A61P 9/00, A61P 11/06, A61P 37/08, A61P 11/00, A61K 9/2013, A61K 9/2018, A61K 9/2059, A61K 9/4825, A61K 9/4858, A61K 9/4866, A61K 31/4439, A61K 31/444, A61K 31/5377, C07D 401/04, C07D 401/14, C07D 403/14, C07D 405/14, C07D 409/14, C07D 413/14, C07D 451/04, C07D 471/04Filed as Shionogi & Co., Ltd.2024-08-27Yuki NAGAMOTO | pending |
| NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOFA61K 9/0019, A61K 31/424, C07D 487/14, C07D 498/14, A61P 21/00, A61P 27/06, A61P 9/10, A61P 25/28, A61P 43/00, A61P 3/00, A61P 9/00, A61P 25/02, A61P 3/06, A61P 3/10, A61P 9/12, A61P 9/04, A61P 11/00, A61P 25/00, A61P 35/00, A61K 9/08, A61K 9/2054, A61K 9/4866, A61K 31/437, A61K 31/4985, A61K 31/5025, A61K 31/5377, A61K 31/5386, A61K 47/26, C07D 471/14, C07D 498/04, C07D 498/12, C07D 519/00, C07D 471/04, C07D 487/04Filed as SHIONOGI & CO., LTD.2024-08-22Maki Yamakawa | pending |
| INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD AND PROGRAMG16H 50/20, G16H 40/67, G16H 10/60, G16H 15/00, G16H 50/30, G16H 10/20, G16H 80/00, A61B 5/112, A61B 5/1124, A61B 5/4082Filed as Shionogi Inc.2024-08-16Satoshi IWASAKI | pending |
| PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTIONA61P 11/00, A61K 31/53, A61P 43/00, A61P 31/12, A61P 31/14, A61K 9/0053, A61K 9/1623, A61K 9/1652, A61K 9/2018, A61K 9/2054, A61K 31/194, A61K 47/12, C07D 403/14Filed as Shionogi & Co., Ltd.2024-07-17Ryosuke SHIMIZU | pending |
| PHARMACEUTICAL PREPARATION EXCELLENT IN LIGHT STABILITY AND DISSOLUTION PROPERTYA61K 6/813, A61K 9/2813, A61K 31/5383, A61P 43/00, A61P 31/16, A61K 9/2054, A61K 9/284, A61K 9/2846, A61K 9/2866, A61K 9/501, A61K 9/5026, A61K 9/5047, C07D 498/14, G01N 30/88, G01N2030/884Filed as Shionogi & Co., Ltd.2024-07-15Naomi HAYASHI | pending |
| POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVEC07D 471/14, C07D 471/18, C07D 487/14, C07D 498/14, A61P 31/18, A61K 31/53, A61K 31/5383, A61K 31/5386, C07D 471/20, C07D 471/22, C07D 491/22, C07D 498/22, C07B2200/07Filed as Shionogi & Co., Ltd.2024-06-26Yoshiyuki TAODA | pending |
| USE OF OPIOID FOR TREATMENT OF AUTISM SPECTRUM DISORDERSA61P 25/18, A61K 31/485, A61P 25/00, A61K2300/00Filed as SHIONOGI & CO., LTD.2024-06-20Yukio AGO | pending |
| AROMATIC HETEROCYCLIC DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST ACTIVITYC07D 401/14, C07D 471/04, A61P 43/00, A61P 3/04, A61P 3/10, A61K 31/4375, A61K 31/454, A61K 31/4545, A61K 31/4725, C07D 401/04, C07D 401/12, C07D 403/04, C07D 403/14, C07D 405/14, C07D 409/14, C07D 413/14, C07D 417/14, C07D 487/04, C07D 495/04, C07D 513/04, C07D 519/00Filed as Shionogi & Co., Ltd.2024-06-06Hiroki KUSANO | pending |
| METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEAFiled as SHIONOGI-APNIMED SLEEP SCIENCE, LLC2024-06-05Luigi TARANTO-MONTEMURRO | pending |
| COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUGA61K 31/495, A61P 31/14, C07K 16/1003Filed as Shionogi & Co., Ltd.2024-05-20Ryuichi YANO | pending |
| THERAPEUTIC MEDICINE FOR HEART DISEASE OR SKELETAL MUSCLE DISEASEA61P 3/06, A61K 31/4184, A61P 7/00, A61P 21/00, A61P 9/10, A61P 43/00, A61P 9/00, A61P 9/06, A61P 3/10, A61P 13/12, A61P 9/04, C07D 235/26, C07D 405/12Filed as SHIONOGI & CO., LTD.2024-05-16Yasunobu YOSHIDA | pending |
| FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITYA61K 31/438, C07D 471/04, C07D 471/10, C07D 471/20, A61P 9/10, A61P 43/00, A61P 3/00, A61P 3/04, A61P 3/06, A61P 3/10, A61K 31/444, A61K 31/497, A61K 31/501, A61K 31/506, A61K 31/527, C07D 487/10, C07D 491/147, C07D 491/20, C07D 519/00Filed as Shionogi & Co., Ltd.2024-05-16Kouhei NODU | 12454533 |
| SPIROHETEROCYCLE DERIVATIVE HAVING SEROTONIN RECEPTOR BINDING ACTIVITYC07D 498/10, A61P 15/10, A61P 25/14, A61P 25/20, A61P 25/28, A61P 25/30, A61P 43/00, A61P 25/18, A61P 25/24, A61P 25/00, A61P 25/16, A61K 31/438, A61K 31/444, A61K 31/506, A61K 31/527, C07D 471/10Filed as Shionogi & Co., Ltd.2024-03-19Tatsuhiko UENO | pending |
| MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITYA61K 31/437, A61K 31/444, A61K 31/499, A61K 45/06, A61P 9/10, A61P 43/00, A61P 3/04, A61P 3/06, A61P 3/10, A61K 31/4184, A61K 31/438, A61K 31/497, A61K 31/4985, A61K 31/501, A61K 38/16, A61K 38/26, A61K 38/28, A61K2300/00Filed as Shionogi & Co., Ltd.2024-02-29Kosuke TAKEMOTO | pending |
| NUCLEOSIDE DERIVATIVES AND PRODRUGS THEREOF HAVING VIRAL GROWTH INHIBITORY ACTIONA61P 31/16, A61K 31/53, A61K 31/675, C07D 487/04, A61P 31/12, C07F 9/6561, C07F 9/65616Filed as Shionogi & Co., Ltd.2024-02-16Issei KATO | pending |
| SOLID DOSAGE FORM HAVING EXCELLENT STABILITYA61K 9/1611, A61K 9/1623, A61K 31/53, A61K 31/5383, A61P 31/12, A61P 31/16, A61K 9/0095, A61K 9/1617, A61K 9/1635, A61K 9/1652, A61K 9/1682, A61K 47/02, A61K 47/12, A61K 47/14, A61K 47/22, A61K 47/26, A61K 47/38Filed as Shionogi & Co., Ltd.2024-02-07Naoya MIZUTANI | 12427156 |
| SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOFA61K 31/53, C07D 498/14, C07C2601/08, C07C2601/16, A61P 31/00, A61P 31/16, A61K 9/0014, A61K 9/0019, A61K 9/0056, A61K 9/0075, A61K 9/0095, A61K 9/06, A61K 9/1611, A61K 9/1623, A61K 9/2018, A61K 9/2054, A61K 9/485, A61K 9/4858, A61K 9/7038, A61K 31/5383, A61K 31/542, A61K 31/553, A61K 31/675, A61K 47/06, A61K 47/26, C07D 471/14, C07D 471/20, C07D 491/22, C07D 513/14, C07D 519/00, C07F 7/18, C07F 7/1804, C07F 9/6561Filed as Shionogi & Co., Ltd.2024-01-26Makoto KAWAI | pending |
| PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOFFiled as Shionogi & Co., Ltd.2024-01-26Makoto KAWAI | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on SGIOY
Company overviewEverything on SGIOY in one place, with the price.Who owns itEvery manager reporting a position in SGIOY.LobbyingWhat SGIOY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on SGIOY's account, and who they worked for.Federal contractsWhat federal agencies pay SGIOY.